Benefit-Risk Analysis of Upadacitinib compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Conaghan, P orcid.org/0000-0002-3478-5665, Cohen, S, Burmester, G et al. (11 more authors) (Accepted: 2021) Benefit-Risk Analysis of Upadacitinib compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. ISSN 2198-6576 (In Press)

Metadata

Authors/Creators:
Dates:
  • Accepted: 8 November 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Musculoskeletal Medicine & Imaging (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 25 Nov 2021 10:21
Last Modified: 25 Nov 2021 10:21
Status: In Press
Publisher: Springer

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export